Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

R. J. Firpi, T. T. Tran, P. Flores, N. Nissen, S. Colquhoun, C. Shackleton, P. Martin, J. M. Vierling, F. F. Poordad

Resultado de la investigación: Articlerevisión exhaustiva

25 Citas (Scopus)


Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.

Idioma originalEnglish (US)
Páginas (desde-hasta)1033-1039
Número de páginas7
PublicaciónAlimentary Pharmacology and Therapeutics
EstadoPublished - may 1 2004
Publicado de forma externa

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)


Profundice en los temas de investigación de 'Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent'. En conjunto forman una huella única.

Citar esto